{
      "Rank": 1,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Participants will receive Prochymal\u00ae single intravenous (IV) infusion at a dose of 200 x 10^6 human mesenchymal stem cells (hMSC), reconstituted in 80 mL, delivered at a rate of 2 mL/min, with a maximum rate of 5.0 x 10^6 hMSC/minute, and the participants will be followed for 24 months and remain in the study for up to 60 months.",
            "Participants will receive Prochymal\u00ae placebo-matching single IV infusion at a dose of of 200 x 10^6 hMSC, reconstituted in 80 mL, delivered at a rate of 2 mL/min, with a maximum rate of 5.0 x 10^6 hMSC/minute, and the participants will be followed for 24 months and remain in the study for up to 60 months."
      ],
      "ArmGroupInterventionName": [
            "Drug: Prochymal\u00ae",
            "Drug: Placebo"
      ],
      "ArmGroupLabel": [
            "Prochymal\u00ae",
            "Placebo"
      ],
      "ArmGroupType": [
            "Experimental",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT00877903"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The objective of the present study is to establish the safety and efficacy of Prochymal\u00ae following first acute myocardial infarction."
      ],
      "BriefTitle": [
            "Prochymal\u00ae (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "March 14, 2016"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Myocardial Infarction"
      ],
      "ConditionAncestorId": [
            "D000007511",
            "D000010335",
            "D000009336",
            "D000017202",
            "D000006331",
            "D000002318",
            "D000014652"
      ],
      "ConditionAncestorTerm": [
            "Ischemia",
            "Pathologic Processes",
            "Necrosis",
            "Myocardial Ischemia",
            "Heart Diseases",
            "Cardiovascular Diseases",
            "Vascular Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC14",
            "BC23",
            "All",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Heart and Blood Diseases",
            "Symptoms and General Pathology",
            "All Conditions",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Myocardial Infarction",
            "Infarction"
      ],
      "ConditionBrowseLeafId": [
            "M11307",
            "M9434",
            "M9695",
            "M11436",
            "M5698",
            "M18658",
            "M8571",
            "M16552",
            "T170"
      ],
      "ConditionBrowseLeafName": [
            "Myocardial Infarction",
            "Infarction",
            "Ischemia",
            "Necrosis",
            "Coronary Artery Disease",
            "Myocardial Ischemia",
            "Heart Diseases",
            "Vascular Diseases",
            "Acute Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000009203",
            "D000007238"
      ],
      "ConditionMeshTerm": [
            "Myocardial Infarction",
            "Infarction"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Quadruple"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Care Provider",
            "Investigator",
            "Outcomes Assessor"
      ],
      "DetailedDescription": [
            "The standard of care treatment for acute myocardial infarction (AMI) usually includes immediate perfusion, optimal pain relief, oxygen, aspirin or other anti-coagulants, Beta-Blockers, nitrates and Ace-inhibitors. However, because salvaging the viable myocardium is dependent on early reperfusion, only a minority of participants will reach the hospital within the time-window for myocardial rescue. Thus, even if the participant manages their tobacco use, hypertension, lipid levels, diabetes, weight and exercise, many participants will go on to develop Congestive Heart Failure (CHF). Though the medical management for CHF may improve symptoms and slow disease progression, such treatment cannot restore a functioning myocardium. A therapy that could improve the myocardial remodeling process and reduce the incidence or severity of CHF following acute MI would provide a significant benefit. The characteristics and biologic activity of Prochymal\u00ae, along with a good safety profile in human trials to date, suggest that Prochymal\u00ae may be a good candidate for addressing this unmet medical need."
      ],
      "DispFirstPostDate": [
            "December 23, 2021"
      ],
      "DispFirstPostDateType": [
            "Actual"
      ],
      "DispFirstSubmitDate": [
            "December 20, 2021"
      ],
      "DispFirstSubmitQCDate": [
            "December 20, 2021"
      ],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nMale or female between 21 and 85 years old, inclusive\nFirst heart attack within 7 days prior to randomization and drug infusion\nBaseline left ventricular ejection fraction (LVEF) 20-45%\nHemodynamically stable within 24 hours prior to randomization\nAdequate pulmonary function\n\nExclusion Criteria:\n\nPrevious medical history of heart attack, heart failure, significant valvular heart disease, aortic dissection\nPacemaker or other device\nPregnant, breast-feeding, or intends to become pregnant during the study\nAllergy to cow or pig derived products\nEvidence of active malignancy or prior history of active malignancy\nMajor surgical procedure or major trauma within the past 14 days\nAutoimmune disease (e.g., Lupus, Multiple Sclerosis)\nAny medical condition, which in the opinion of the Investigator, renders participation unsuitable\nUndergone pharmacologic cardioversion or external defibrillation within 24 hours of randomization.\nExperienced cardiac arrest more than 36 hours after presentation to site or within 24 hours of randomization."
      ],
      "EnrollmentCount": [
            "220"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000000893",
            "D000000998",
            "D000000890"
      ],
      "InterventionAncestorTerm": [
            "Anti-Inflammatory Agents",
            "Antiviral Agents",
            "Anti-Infective Agents"
      ],
      "InterventionArmGroupLabel": [
            "Prochymal\u00ae",
            "Placebo"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Infe",
            "Infl",
            "All"
      ],
      "InterventionBrowseBranchName": [
            "Anti-Infective Agents",
            "Anti-Inflammatory Agents",
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [
            "1440"
      ],
      "InterventionBrowseLeafId": [
            "M186752",
            "M3369",
            "M3466",
            "M3366"
      ],
      "InterventionBrowseLeafName": [
            "Remestemcel-l",
            "Anti-Inflammatory Agents",
            "Antiviral Agents",
            "Anti-Infective Agents"
      ],
      "InterventionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells",
            "Intravenous infusion of excipients of Prochymal\u00ae"
      ],
      "InterventionMeshId": [
            "C000711674"
      ],
      "InterventionMeshTerm": [
            "Remestemcel-l"
      ],
      "InterventionName": [
            "Prochymal\u00ae",
            "Placebo"
      ],
      "InterventionOtherName": [
            "Remestemcel-L"
      ],
      "InterventionType": [
            "Drug",
            "Drug"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "Yes"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Acute myocardial infarction",
            "AMI",
            "Myocardial infarction",
            "Heart attack",
            "Mesenchymal stem cells",
            "MSC",
            "Adult human stem cells",
            "Osiris"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "January 13, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "January 11, 2022"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Mesoblast, Inc."
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Gilbert",
            "Tucson",
            "Sacramento",
            "San Diego",
            "Miami Beach",
            "Miami",
            "Chicago",
            "Indianapolis",
            "Iowa City",
            "Topeka",
            "Baltimore",
            "Boston",
            "Springfield",
            "Worcester",
            "Royal Oak",
            "Saginaw",
            "Minneapolis",
            "New Brunswick",
            "Buffalo",
            "Stony Brook",
            "Winston-Salem",
            "Cincinnati",
            "Columbus",
            "Portland",
            "Hershey",
            "Philadelphia",
            "Pittsburgh",
            "Germantown",
            "Austin",
            "Houston",
            "Burlington",
            "Madison",
            "Montreal"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "Canada"
      ],
      "LocationFacility": [
            "Mercy Gilbert Medical Center / Catholic Health Care West",
            "University of Arizona",
            "UC Davis Medical Center",
            "University of California - San Diego (UCSD)",
            "Mount Sinai Medical Center",
            "University of Miami",
            "Rush University Medical Center",
            "The Care Group",
            "University of Iowa Hospitals and Clinics",
            "Cotton-O'Neil Clinical Research Center",
            "University of Maryland Hospital",
            "Tufts Medical Center",
            "Baystate Medical Center",
            "UMass Memorial Medical Center",
            "William Beaumont Hospital",
            "Michigan Cardiovascular Institute",
            "Minneapolis Heart Institute",
            "UMDNJ - Robert Wood Johnson Medical School",
            "University at Buffalo - Buffalo General Hospital",
            "Stony Brook University Medical Center",
            "Wake Forest University School of Medicine",
            "The Lindner Research Center",
            "The Ohio State University Medical Center",
            "Oregon Health & Science University",
            "Penn State University - Milton S. Hershey Medical Center",
            "Drexel University College of Medicine",
            "Allegheny General Hospital",
            "The Stern Cardiovascular Center",
            "Austin Heart P.A.",
            "University of Texas Health Science Center",
            "Fletcher Allen Health Care",
            "University of Wisconsin School of Medicine",
            "McGill University Health Centre"
      ],
      "LocationState": [
            "Arizona",
            "Arizona",
            "California",
            "California",
            "Florida",
            "Florida",
            "Illinois",
            "Indiana",
            "Iowa",
            "Kansas",
            "Maryland",
            "Massachusetts",
            "Massachusetts",
            "Massachusetts",
            "Michigan",
            "Michigan",
            "Minnesota",
            "New Jersey",
            "New York",
            "New York",
            "North Carolina",
            "Ohio",
            "Ohio",
            "Oregon",
            "Pennsylvania",
            "Pennsylvania",
            "Pennsylvania",
            "Tennessee",
            "Texas",
            "Texas",
            "Vermont",
            "Wisconsin",
            "Quebec"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "85297",
            "85724",
            "95817",
            "92103",
            "33140",
            "33136",
            "60612",
            "46290",
            "52242",
            "66604",
            "21201",
            "02111",
            "01199",
            "01655",
            "48073",
            "48601",
            "55407",
            "08903",
            "14203",
            "11794",
            "27157",
            "45219",
            "43210",
            "97239",
            "17033",
            "19102",
            "15212",
            "38138",
            "78756",
            "77030",
            "05401",
            "53792",
            "H3A 1A1"
      ],
      "MaximumAge": [
            "85 Years"
      ],
      "MinimumAge": [
            "21 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of PROCHYMAL\u00ae (Ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Mesoblast, Ltd."
      ],
      "OrgStudyId": [
            "403"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Mesoblast, Inc."
      ],
      "OverallOfficialName": [
            "Ken Borow, MD"
      ],
      "OverallOfficialRole": [
            "Study Director"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "May 18, 2011"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [],
      "PrimaryOutcomeMeasure": [
            "Change from Baseline in Cardiac Magnetic Resonance (CMR) imaging-determined End Systolic Volume (ESV) at Month 3"
      ],
      "PrimaryOutcomeTimeFrame": [
            "Baseline, Month 3"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "The Duke Activity Status Index (DASI) is a brief, self-administered questionnaire that provides a standardized assessment of functional status and quality-of-life that correlates well with an objective measure of maximal exercise capacity. The scale ranges from 0 (unable to perform any tasks) to 58.20 (able to perform all tasks). Higher scores indicate a greater ability to perform daily activities."
      ],
      "SecondaryOutcomeMeasure": [
            "Left Ventricular End Systolic Volume",
            "Infarct Size",
            "Left Ventricular Ejection Fraction",
            "Left Ventricular End Diastolic Volume",
            "Number of Participants with Ventricular Arrhythmias",
            "Duke Activity Status Index (DASI) Assessment",
            "New York Heart Association (NYHA) Congestive Heart Failure Classification Status",
            "Maximal Symptom-limited Exercise Test (Treadmill)",
            "Number of Participants with Major Adverse Cardiac Events (MACE)",
            "Overall Survival",
            "Number of Participants with Adverse Events"
      ],
      "SecondaryOutcomeTimeFrame": [
            "6 months",
            "3 and 6 months",
            "3 and 6 months",
            "3 and 6 months",
            "3 and 6 months",
            "6, 12, and 24 months",
            "6, 12, 24, and 60 months",
            "6 and 12 months",
            "6, 12, 24, and 60 months",
            "60 months",
            "3,6,12,24,60 months"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "March 30, 2009"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "January 2022"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "April 8, 2009"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "April 7, 2009"
      ],
      "StudyFirstSubmitQCDate": [
            "April 7, 2009"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}